Search

Zactran®

Depending on species indication (and country of registration), the product is for the treatment and metaphylaxis control of respiratory disease in cattle caused by key bacteria (Mannheimia, Pasteurella, Histophilus and Mycoplasma) and footrot disease

Lysophospholipase inhibitor

Algorithms to battle heartworm disease

Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets

BULTAVO 3

Indicated for bluetongue disease serotype 3 in sheep and cattle

LastMile increases access to veterinary care in Africa

Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine

DCRI-collaboration-empact-mi

Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction

Patient centricity and site centricity in clinical trials

We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.

Boehringer Ingelheim good 2021 business performance

2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.

Striverdi® Respimat®

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million

Rabies prevention local action partnering organizations

Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.

Anti-fibrotic agent

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype

Heart murmur in dogs: symptoms and how to treat it

Monitoring your dog’s heart can save its life

Ivan Blanarik Therapeutic Area Head Respiratory

Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim

Diabetes dog symptoms chronic disease management

Learn about the symptoms of canine diabetes and how to manage the disease.

Retinal health: All eyes on vision loss

Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites

Three challenges shape future antiparasitic treatment

The three key challenges that will shape the future of antiparasitic treatment

GLP-1/FGF21 agonist

Win Fight Against Cancer

At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.

BI 690517 + Empagliflozin

BI 690517 + Empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor

Spiolto® Respimat®

Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Veterinary Public Health

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers